Zentalis Pharmaceuticals (ZNTL) Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ZNTL Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Zentalis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.61 |
| 52 Week High | US$4.44 |
| 52 Week Low | US$1.01 |
| Beta | 1.77 |
| 1 Month Change | -8.00% |
| 3 Month Change | 35.29% |
| 1 Year Change | -52.23% |
| 3 Year Change | -92.54% |
| 5 Year Change | -96.01% |
| Change since IPO | -93.06% |
Recent News & Updates
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Aug 27
Is Zentalis Pharmaceuticals (NASDAQ:ZNTL) In A Good Position To Deliver On Growth Plans?
Aug 16Recent updates
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Aug 27Is Zentalis Pharmaceuticals (NASDAQ:ZNTL) In A Good Position To Deliver On Growth Plans?
Aug 16We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully
Oct 03Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher
Jun 19We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jun 13Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit
May 09Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Apr 12We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Feb 29Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
Feb 05Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?
Jan 09We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Oct 13We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Jun 30We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Mar 17We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Dec 01Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer
Sep 27Zentalis Pharmaceuticals has a new chief medical officer
Sep 19Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
Aug 17Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
May 02We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jan 12We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Oct 14Shareholder Returns
| ZNTL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.9% | 5.2% | 1.2% |
| 1Y | -52.2% | -0.3% | 17.9% |
Return vs Industry: ZNTL underperformed the US Biotechs industry which returned -0.3% over the past year.
Return vs Market: ZNTL underperformed the US Market which returned 17.9% over the past year.
Price Volatility
| ZNTL volatility | |
|---|---|
| ZNTL Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZNTL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ZNTL's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 166 | Julie Eastland | zentalis.com |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.
Zentalis Pharmaceuticals, Inc. Fundamentals Summary
| ZNTL fundamental statistics | |
|---|---|
| Market cap | US$116.14m |
| Earnings (TTM) | -US$162.78m |
| Revenue (TTM) | US$26.87m |
Is ZNTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZNTL income statement (TTM) | |
|---|---|
| Revenue | US$26.87m |
| Cost of Revenue | US$0 |
| Gross Profit | US$26.87m |
| Other Expenses | US$189.65m |
| Earnings | -US$162.78m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.26 |
| Gross Margin | 100.00% |
| Net Profit Margin | -605.93% |
| Debt/Equity Ratio | 0% |
How did ZNTL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 02:57 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zentalis Pharmaceuticals, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Andrew Fein | H.C. Wainwright & Co. |
| Andres Maldonado | H.C. Wainwright & Co. |